Treatment with LCZ696 of patients with symptomatic, advanced heart failure due to left ventricular systolic dysfunction for 24 weeks, compared to valsartan.
The primary objective of the study is to determine whether, in patients with symptomatic, advanced heart failure due to left ventricular systolic dysfunction, treatment with LCZ696 for 24 weeks will improve Pro-B-type Natriuretic Peptide (NT-proBNP) levels, which reflect hemodynamic and clinical status, compared to treatment with valsartan.
Location: SIMR (Sacramento/ Valley Area)
Please contact firstname.lastname@example.org about the LIFE Study
View study details on ClinicalTrials.gov
April 28, 2017
Investigator(s): Andrew Hudnut, MD